Browse more peptide research, methods and limitations.
Both liraglutide and semaglutide reduced antipsychotic-induced weight gain and adiposity biomarkers in the short term.
Airosus, Charlotte; Ardabili, Negar Ghasam; Hyde, Alexia; Davidson, Terry L · Animal Study
Anti-CGRP medications effectively reduced headache frequency and severity in patients with intractable chronic daily headache refractory to other preventive treatments.
Akbar, Asra; Deshpande, Girish; Tripathi, Sandeep · Case Series
Red pomegranate protein hydrolysates demonstrated triple bioactivity: antibacterial, ACE-inhibitory, and DPP-4-inhibitory properties from food-derived peptides.
Akbarbaglu, Zahra; Mazloomi, Narges; Karimzadeh, Laleh; Sarabandi, Khashayar; Jafari, Seid Mahdi; Hesarinejad, Mohammad Ali · In Vitro
GLP-1 RA use significantly altered GI transit times during video capsule endoscopy, affecting preparation quality and requiring protocol adaptations for diagnostic accuracy.
Akerman, Nimrod; Fliss-Isakov, Naomi; Thurm, Tamar; Shnell, Mati; Sofer, Yael; Shibolet, Oren; Deutsch, Liat · Cohort
GLP-1 and urolithin A metabolic reprogramming of CAR-T cells improved their energy fitness, reduced exhaustion, and enhanced anti-tumor killing activity.
Akhtar, Areej; Shakir, Md; Ansari, Mohammad Sufyan; Divya; Faizan, Md Imam; Chauhan, Varnit; Singh, Aashi; Alam, Ruquaiya; Azmi, Iqbal; Sharma, Sheetal; Pracha, Mehak; Uddin, Insha Mohi; Bashir, Uzma; Shahni, Syeda Najidah; Chaudhuri, Rituparna; Albogami, Sarah; Ganguly, Rik; Sagar, Shakti; Singh, Vijay Pal; Kharya, Gaurav; Srivastava, Amit Kumar; Mabalirajan, Ulaganathan; Roy, Soumya Sinha; Rahman, Irfan; Ahmad, Tanveer · In Vitro
Localized semaglutide injection improved lymphatic function at hyperinsulinemia-induced sites, demonstrating a novel tissue-repair application.
Akl, Maher Monir; Ahmed, Amr · Review
GLP-1 RA use associated with improved clinical outcomes across multiple conditions including reduced hospitalizations and cardiovascular events.
Aksan, Feyzullah; Abboud, Alan; Tanriverdi, Lokman H; Aroniadis, Olga C; Monzur, Farah · Cohort
Bariatric surgery achieves greater weight loss (25-35%) but GLP-1 drugs (15-21%) are narrowing the gap and offer non-surgical advantages, with combination approaches emerging as optimal.
Akwe, Joyce; Fongeh, Kimela; Jung, Sarah; Hall, Mary Ann Kirkconnell; Patidar, Viniya; Shin, Yoo Mee · Review
Semaglutide add-on therapy improved glycemic control, body weight, blood pressure, and lipid profiles in inadequately controlled T2D patients.
Al Hayek, Ayman; Klonoff, David C; Al Zahrani, Wael M; Ibrahim, Suzan Eid; Al Dawish, Mohammed A · Cohort
The obesity drug pipeline has expanded from single GLP-1 agonists to dual/triple agonists and amylin combinations, with oral formulations emerging for improved access.
Al Lawati, Abdullah; Alhabsi, Ayman; Rahul, Rhieya; Savino, Maria-Luisa; Alwahaibi, Hamed; Das, Srijit; Al Lawati, Hanan · Review
GLP-1 drugs have expanded across endocrinology, cardiology, nephrology, neurology, psychiatry, and hepatology with proven or promising outcomes in each specialty.
Al Qassab, Mohamad; Mneimneh, Mohammad; Jradi, Ahmad; Derbas, Bassem; Dabboussi, Dana; Khoury Baini, Justine; Katrib, Nadia; Chaarani, Nadim; Attieh, Philippe; Kanaan, Amjad; Harb, Frederic; Azar, Sami; Ghadieh, Hilda E · Review
GLP-1 RA treatment increases adiponectin levels, which may mediate the insulin-sensitizing, anti-inflammatory, and vascular protective effects of these drugs.
Al Refaie, Antonella; Baldassini, Leonardo; Mondillo, Caterina; Ceccarelli, Elena; Tarquini, Roberto; Gennari, Luigi; Gonnelli, Stefano; Caffarelli, Carla · Cohort
GLP-1 drugs are established as multi-benefit T2D therapies with varying efficacy profiles across agents, supporting individualized drug selection.
Al Refaie, Antonella; Baldassini, Leonardo; Mondillo, Caterina; Gonnelli, Sara; Ceccarelli, Elena; Tarquini, Roberto; Gonnelli, Stefano; Gennari, Luigi; Caffarelli, Carla · Review
AI has accelerated discovery of food-derived bioactive peptides with diverse health benefits, enabling rapid identification of functions that would take decades to find experimentally.
Al Shareef, Rolan; Fathelrahman, Eihab; Osman, Raeda; Gebiso, Tamrat; Platat, Carine · Review
Real-world semaglutide use produced significant clinical improvements in T2D, with budget impact analysis showing cost justification through prevented complications.
Al-Abdulkarim, Hana A; Alqahtani, Nawaf Salih; Al-Shraim, Mohammad; Almohammed, Omar A · Cohort
Weight loss contributes to but does not fully explain GLP-1 drug HbA1c improvement. Significant direct glucose-lowering effects operate independently of weight change.
Al-Badri, Marwa; Dhaver, Shilton; Hamdy, Osama · Cohort
PACAP38-induced migraine attacks were not blocked by CGRP signaling inhibition, demonstrating an independent neuropeptide migraine pathway that represents a new drug target.
Al-Karagholi, Mohammad Al-Mahdi; Zhuang, Zixuan Alice; Beich, Signe; Ashina, Håkan; Ashina, Messoud · RCT
NPY and PACAP serum levels changed significantly during CF pulmonary exacerbations and correlated with clinical outcomes, linking neuropeptide signaling to CF lung inflammation.
Al-Keilani, Maha S; Bdeir, Roba; Almomani, Basima A; Awad, Samah; Hammouri, Hanan; Al Shalakhti, Tala; Dahabreh, Muna M; Ajlony, Mohammad-Jaafar A · Cohort
Tirzepatide combats atherosclerosis through anti-inflammatory, endothelial protective, lipid-modifying, and plaque-stabilizing mechanisms via dual GLP-1/GIP receptor activation.
Al-Kuraishy, Hayder M; Sulaiman, Ghassan M; Mohammed, Hamdoon A; Saad, Hebatallah M; Waheed, Huda J; Jabir, Majid S; Al-Gareeb, Ali I; Albuhadily, Ali K · Review
GLP-1 RA use associated with reduced progression to liver transplant in NAFLD/NASH patients, supporting hepatoprotective benefits of these peptide drugs.
Al-Moussally, Feras; Khan, Saud; Katukuri, Vinay; Kinaan, Mustafa; Mansi, Ishak A · Cohort
Different lifestyle approaches combined with liraglutide produced varying outcomes, identifying optimal diet and exercise strategies for maximizing GLP-1 drug benefits.
Al-Najim, Werd; Dehestani, Babak; Al-Humadi, Ahmed W; Bodicoat, Danielle H; Papamargaritis, Dimitris; Lean, Michael; McGowan, Barbara; Webb, David R; Wilding, John Ph; Davies, Melanie J; le Roux, Carel W · RCT
Real-world analysis of off-label semaglutide use for weight loss reveals user behavior patterns, effectiveness outside clinical trials, and adherence challenges.
Al-Qaaneh, Ayman M; Qunaibi, Eyad A; Al-Fraihat, Natalia A; Abu-Aisheh, Baraa E; Rabea, Sameh; Al Aloul, Adnan A; Matahen, Rajaa; Annabi, Firas O · Cohort
Exenatide combined with metformin improved insulin resistance more effectively than metformin alone, demonstrating complementary mechanisms for early diabetes management.
Al-Qudah, Abd-Alrahman; Al-Hanaktah, Mohammad; Albadaineh, Reham · Meta Analysis
Semaglutide initiation caused lithium toxicity in patients on lithium therapy due to altered renal clearance, highlighting a critical drug interaction for psychiatric patients.
Al-Soleiti, Majd; Leung, Jonathan G; Mubaydeen, Teeba; Markota, Matej; Abulseoud, Osama; Singh, Balwinder; Sola, Christopher L · Case Series
Systematic review confirms subcutaneous semaglutide significantly reduces blood pressure, providing an additional cardiovascular benefit beyond weight and glucose effects.
Ala, Moein; Moheb Aleaba, Mohammadreza · Meta Analysis
Review of peptides in breast cancer therapy covers tumor-targeting peptides, peptide-drug conjugates, antimicrobial peptides, and emerging peptide-based drug delivery systems.
Alaei, Elmira; Hashemi, Farid; Farahani, Najma; Tahmasebi, Safa; Nabavi, Noushin; Daneshi, Salman; Mahmoodieh, Behnaz; Rahimzadeh, Payman; Taheriazam, Afshin; Hashemi, Mehrdad · Review
Comparison of three leading GLP-1/GIP drugs for weight loss found tirzepatide produced the most weight loss, followed by semaglutide, then liraglutide, with varying side effect profiles.
Alali, Saleh; Al-Otaibi, Wed; Ashodian, Karen; Achour, Nour; Almulla, Aishah; Mutlaq, Hessa · Cohort
Meta-analysis shows GLP-1 receptor agonists reduce ischemic stroke incidence and improve post-stroke outcomes in diabetes patients, adding stroke protection to their cardiovascular benefits.
Alammari, Nawal; Alshehri, Atheel; Al Khalaf, Abdulhameed; Alamri, Rahaf Abdulaziz; Alhalal, Noor; Sultan, Majd Abdullah; Ogran, Nesreen; Aljohani, Razan Mubarak S; Alasmari, Sarah Mohammed Saad; Alsharif, Sarah Badr; Al-Qahtani, Zainah; Azzam, Ahmed Y · Meta Analysis
Meta-analysis of GLP-1 agonists and suicidal ideation finds no significant association, providing further reassurance on the psychiatric safety of these widely used drugs.
Alansari, Amal Omar; Alharbi, Ahlam Saleem; Alshehri, Khaled Mohammad; Alhabib, Ali Tareq; Alsalmi, Bodour Saleh; Almosfer, Waleed Abdulaziz; AlAjlan, Fadiyah Abdullah; Alharbi, Abeer Abdullah; Alzahrani, Basmah Saleh; Alamer, Bader; Alatawi, Amirah M · Meta Analysis
Study evaluating semaglutide on a composite endpoint of glycemic control and weight management found it effective at achieving both goals simultaneously in T2D patients.
Alarfaj, Sumaiah J · Cohort
Tirzepatide countered inflammatory and apoptotic responses induced by high-fat conditions, demonstrating direct cellular protective effects of GLP-1/GIP dual agonism.
Alathary, Ashraf; Al-Isawi, Zahraa · Animal Study
Review assesses tirzepatide's potential for modulating inflammatory responses through GLP-1/GIP dual agonism, with implications for inflammatory diseases beyond diabetes.
Alawaji, Razan; Abdel-Bakky, Mohamed S; Ali, Hussein M; Aljuhani, Miad A; Alshammari, Abdulaziz Arif A; Kamal, Hashim K; Khoja, Maamoun M K; Alsehemi, Kholoud; Korani, Mennatallah A; Said, Eman S · Animal Study
Study maps GLP-1 receptor expression and functional diversity across human tissues, explaining why GLP-1 drugs affect so many organ systems.
Alba, Mario M; Lee, Wilson H; Lee, Jerry S H; Lu, Zhipeng; Stiles, Bangyan; Ligumsky, Hagai · Review
Analysis of antidiabetic therapy effects on liver injury, steatosis, and fibrosis shows GLP-1 drugs among the most liver-protective options for diabetic patients.
Albai, Oana; Braha, Adina; Timar, Romulus; Lazăr, Sandra; Popescu, Simona; Timar, Bogdan · Cohort
Review of GLP-1 agonist implications for aesthetic surgery covers preoperative considerations, anesthesia impacts, wound healing, and body contouring outcomes.
Albanese, Roberta; Tomaselli, Federica; Delia, Gabriele; Tambasco, Damiano · Cohort
Combination of SGLT2 inhibitor dapagliflozin and GLP-1 agonist liraglutide showed potential for enhanced cardio-renal protection through complementary mechanisms.
Albanna, Adel Ali; Ibrahim, Doa'a Anwar; Shamsher, Amani Mohammed; Al-Shawia, Mojahed Ali; Halboup, Abdulsalam · Animal Study
Semaglutide treatment improved liver enzyme levels and cardiometabolic markers in obese individuals, demonstrating hepatic and metabolic benefits during weight loss.
Albarmawi, Husam; Dabbous, Firas; Aly, Abdalla; Yousif, Alia; Huse, Samuel; Jara, Maximilian; Quintero, Andres; Lawitz, Eric · Cohort
Expert consensus from Saudi Arabia provides migraine management guidelines including positioning of anti-CGRP therapies within the local healthcare context.
Albilali, Abdulrazaq S; Alkawi, Ammar M; Alotaibi, Naser D; Qureshi, Shireen Am; Alabdali, Majed M; Alabdaly, Hani M; Alenzi, Bader A; Al Khathaami, Ali M; Elchami, Ziad M; Alesefir, Walid A · Review
Review examines evidence that antidiabetic drugs including GLP-1 agonists may prevent and intercept cancer development, linking metabolic drug therapy to oncology.
Albini, Adriana; Cantelmo, Anna Rita; Mortara, Lorenzo; Noonan, Douglas M; Corso, Giovanni · Review
Study of cathelicidin PMAP-36 and BMAP-27 fragments plus D-enantiomers reveals design strategies for more stable, potent antimicrobial peptides.
Albini, Francesca; Biondi, Barbara; Di Stasi, Adriana; Schivo, Andrea; Mardirossian, Mario; Scocchi, Marco; Peggion, Cristina · In Vitro
Study of appetitive traits and quality of life in women with obesity using GLP-1 drugs found significant changes in hunger patterns, food preferences, and overall well-being.
Aldewachi, A; Aladul, M · Cohort
Review addresses treating obesity in heart failure patients where the obesity paradox applies, evaluating how GLP-1 drugs can provide metabolic benefits without worsening cardiac outcomes.
Alebna, Pamela L; Martey, Sarah; Mehta, Anurag; Lavie, Carl J; Carbone, Salvatore · Review
Review of diuretic resistance in cardiorenal syndrome covers natriuretic peptide biology, GLP-1 drug effects, and phenotype-guided management strategies.
Aletras, Georgios; Bachlitzanaki, Maria; Stratinaki, Maria; Foukarakis, Emmanuel; Petrakis, Ioannis; Pantazis, Yannis; Hamilos, Michalis; Stylianou, Kostas · Review
Practical framework for integrating natriuretic peptides and novel biomarkers into heart failure diagnosis and management, bridging research evidence to clinical implementation.
Aletras, Georgios; Bachlitzanaki, Maria; Stratinaki, Maria; Lamprogiannakis, Emmanuel; Petrakis, Ioannis; Foukarakis, Emmanuel; Pantazis, Yannis; Hamilos, Michael; Stylianou, Kostas · Review
Survey of pharmacist knowledge, attitudes, and practices toward CGRP inhibitors for migraine management reveals education gaps and practice patterns in community pharmacy.
Alfahmi, Anwar Seraj; Alqarni, Lana Abdullah; Alkhatabi, Lura Abdulrahman; Alshehri, Fahad S · Cohort
Review of host defense peptides in malaria infection examines their contributions to immune protection, significance for disease outcomes, and potential as therapeutic targets.
Alfaki, Dia Aldeen; Elbasheir, Mohamed Mubarak · Review
Analysis of bowel obstruction and ileus events in GLP-1 drug users evaluates this safety signal using clinical data and pharmacovigilance reports.
Alfehaid, Lama; Alyami, Majed; Almohareb, Sumaya; Alshaya, Omar; Almutairi, Abdulaali · Meta Analysis
Comprehensive review of how GLP-1 receptor agonism is transforming both T2D and cardiovascular disease management through dual metabolic and cardiac protective mechanisms.
Alharbi, Abdulrahman G · Review
Survey reveals knowledge gaps and practice barriers among clinicians prescribing GLP-1 drugs, identifying education needs for optimal patient care.
Alhomoud, Ibrahim S; Aldakhil, Sura A; Alhosan, Reema F; Alrashidi, Hanan S; Alsaqabi, Nada S; Aldugishem, Arjwan M; Alsuhibani, Abdulrahman A; Alrasheedy, Alian A · Cohort
Analysis of real-world prescribing patterns for SGLT2 inhibitors and GLP-1 drugs reveals uptake trends, prescriber preferences, and gaps between guidelines and practice.
Alhomoud, Ibrahim S; Alamer, Khalid A · Cohort